Klinikum Suedstadt Rostock
- Address
- lock Available on a paid plan
Breast Cancer Research
At Klinikum Suedstadt Rostock, much of the trial activity focuses on neoplasms, especially breast cancer across early, high-risk, and residual disease settings. These studies are designed to test new treatment strategies, improve recurrence prevention, and refine adjuvant and neoadjuvant care for patients with hormone receptor-positive and HER2-related disease.
- ER-positive/HER2-negative early breast cancer
- HER2-positive and HER2-negative breast cancer
- Triple negative breast cancer
- High-risk and lobular breast cancer
Research here includes evaluating whether newer targeted and endocrine-based approaches can improve invasive disease-free survival, reduce relapse risk, and support more personalized treatment selection.
Gynecologic Oncology
The site’s gynecologic oncology program is actively studying ovarian cancer and related fallopian tube and peritoneal cancer. The trials aim to improve first-line treatment effectiveness, extend progression-free survival, and explore better maintenance strategies for newly diagnosed advanced disease.
- Newly diagnosed advanced high-grade epithelial ovarian cancer
- Primary peritoneal cancer
- Fallopian tube cancer
These studies are focused on testing whether newer combinations can provide stronger disease control after standard surgery and chemotherapy.
Digestive System Cancer Studies
Another important research area is digestive system diseases, with trials in colorectal cancer and cholangiocarcinoma. The goal is to improve outcomes after surgery, identify who may benefit from additional treatment, and assess new targeted options for difficult-to-treat advanced disease.
- Colon cancer stage II
- Rectal cancer stage II
- Advanced unresectable KRAS G12C-mutated colorectal cancer
- Curative IDH1-mutated cholangiocarcinoma
Studies in this area are examining adjuvant therapy decisions, biomarker-guided treatment, and targeted approaches intended to improve survival and reduce recurrence.
Cardiovascular and Hematology Research
The broader portfolio also includes cardiovascular diseases and hemic and lymphatic diseases. In cardiovascular research, the focus is on heart failure with obesity, while hematology trials are centered on aggressive lymphoma subtypes. These studies aim to evaluate treatment effectiveness and safety in patients with serious, high-need conditions.
- Heart failure with preserved or mildly reduced ejection fraction and obesity
- Diffuse large B-cell lymphoma and related large B-cell lymphoma subtypes
At this hospital in Rostock, investigators are testing whether newer therapies can better control symptoms, slow disease progression, and improve quality of life in these distinct patient groups.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 55 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1GBG Forschungs GmbH2active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GBG Forschungs GmbH3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Suedstadt Rostock
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 3 | Unknown | 2024-01-29 | 2025-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.